The observation of increasing local therapy use for cN1M0PC over time in our study needs to be interpreted in the settings of advancement in staging imaging for prostate cancer,18 with almost three‐quarters of men in the study had PSMA‐PET staging in the 2018–2022 period. This evidence concerns the gene FOLH1 and prostate carcinoma.